APA
Bandari D., Wynn D., Miller T., Singer B., Wray S., Bennett R., Hayward B. & Dangond F. (20150417). Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. : Multiple sclerosis and related disorders.
Chicago
Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, Hayward B and Dangond F. 20150417. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. : Multiple sclerosis and related disorders.
Harvard
Bandari D., Wynn D., Miller T., Singer B., Wray S., Bennett R., Hayward B. and Dangond F. (20150417). Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. : Multiple sclerosis and related disorders.
MLA
Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, Hayward B and Dangond F. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. : Multiple sclerosis and related disorders. 20150417.